The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://rebeccaooki415363.celticwiki.com/2012114/glp_3_retatrutide_a_comparative_analysis